8-K: Performant Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results

Performant Healthcare, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024, showing revenue growth but a decrease in net income compared to the previous year.

Summary

• Performant Healthcare reported total revenues of $34.8 million for Q4 2024, compared to $32.6 million in Q4 2023.
• Healthcare revenues specifically were $34.3 million, up from $31.1 million in the prior year period.
• The company experienced a net loss of $0.5 million, or $(0.01) per diluted share, in Q4 2024, compared to a net income of $1.3 million, or $0.02 per diluted share, in Q4 2023.
• Adjusted EBITDA for Q4 2024 was $3.1 million, down from $4.5 million in the prior year period.
• For the full year 2024, total revenues reached $123.0 million, compared to $113.7 million in 2023.
• Healthcare revenues for the full year were $118.3 million, up from $106.4 million in the previous year.
• The company's net loss for the full year was $9.9 million, or $(0.13) per diluted share, compared to a net loss of $7.5 million, or $(0.10) per diluted share in the prior year.
• Adjusted EBITDA for the full year was $4.4 million, compared to $3.4 million in the prior year.
• The company had approximately $9.3 million in cash, cash equivalents, and restricted cash as of December 31, 2024.
• Performant is guiding for full-year 2025 revenue to be in the range of $131M to $135M and adjusted EBITDA to be in the range of $8M to $9M.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is positive, the increased net loss tempers the overall outlook. The forward guidance is optimistic, but the company needs to demonstrate improved profitability.

Positives

• Total revenues increased for both Q4 2024 and the full year 2024 compared to the prior year periods.
• Healthcare revenues experienced double-digit growth, driven by an 18% increase from commercial clients.
• The company successfully expanded its commercial client base, which now represents over 57% of healthcare revenue.
• Performant had over 100 commercial implementations since 2022, including 42 in 2024.
• The company is projecting significant adjusted EBITDA growth for 2025, nearly doubling year over year at the midpoint of guidance.
• Performant delivered results within the originally guided range in 2024.
• The company had $9.3 million in cash, cash equivalents and restricted cash as of December 31, 2024.

Negatives

• Net loss increased for both Q4 2024 and the full year 2024 compared to the prior year periods.
• Adjusted EBITDA decreased in Q4 2024 compared to the prior year period.
• Revenues from Customer Care / Outsourced Services decreased in both Q4 and full year 2024 compared to the prior year periods.

Risks

• The company's ability to generate revenue is dependent on long implementation periods associated with new customer contracts.
• Many customer contracts are subject to periodic renewal, are not exclusive, and do not provide for committed business volumes.
• Downturns in domestic or global economic conditions and other macroeconomic factors could negatively impact the company.
• The company's indebtedness and compliance with restrictive covenants in its credit agreement pose a risk.
• Failure of the company's operating systems or technology infrastructure, or those of third-party vendors and subcontractors, could have negative impacts.
• Cybersecurity breaches or related incidents could harm the company.
• The company's ability to comply with and adapt to industry regulations and compliance demands is a risk factor.

Future Outlook

Performant Healthcare anticipates full-year 2025 revenue to be in the range of $131 million to $135 million and adjusted EBITDA to be in the range of $8 million to $9 million.

Management Comments

• Simeon Kohl, Chief Executive Officer, stated that 2024 was a year of organization advancement and business growth driven by commercial clients and that investments in technology innovation will continue to drive adjusted EBITDA expansion.
• Rohit Ramchandani, Chief Financial Officer, noted that Performant delivered results within the originally guided range in 2024 despite macro factors impacting the broader payment integrity space.
• Rohit Ramchandani, Chief Financial Officer, stated that the focus for 2025 is on delivering margin improvement through technology advancements and the natural scale of the business.

Industry Context

The company operates in the healthcare payment integrity services industry, which is subject to macro factors and competition. Performant is focused on expanding its commercial client base and leveraging technology to improve margins.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing Performant's specific market segments and client types.
• However, companies like Cotiviti and Optum (UnitedHealth Group) are major players in payment integrity.
• Their revenue and EBITDA margins would be benchmarks to compare against Performant's performance and guidance.
• Cotiviti, for example, focuses on analytics-driven payment accuracy, while Optum offers a broader range of healthcare services.
• Performant's focus on commercial clients and technology innovation could differentiate it from competitors.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss but encouraged by the revenue growth and future guidance.
• Employees may be affected by the company's focus on technology advancements and margin improvement.
• Customers will likely benefit from the company's continued investment in technology and services.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will launch its first State Medicaid contract with the New York State RAC.
• The company will ramp up numerous commercial implementations at various stages of scale.
• The company will focus on delivering margin improvement through technology advancements and the natural scale of the business.
• The company aims to achieve a 20% adjusted EBITDA margin target with the continued success of Project Turing and as implementations and revenue scale.

Key Dates